Clinical Trial Update: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) [Phase 2]

View source ↗

Summary

Phase 2 basket study evaluating entrectinib in solid tumors harboring NTRK1/2/3, ROS1, or ALK gene rearrangements; the study is listed as Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Papillary Thyroid Cancer
• Sarcoma

Drugs mentioned

• Rozlytrek (entrectinib) (entrectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer, Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING